Your browser doesn't support javascript.
loading
Malignant mesothelioma: development to therapy.
Thompson, Joyce K; Westbom, Catherine M; Shukla, Arti.
Afiliación
  • Thompson JK; Pathology Department, University of Vermont, College of Medicine, Burlington, Vermont.
J Cell Biochem ; 115(1): 1-7, 2014 Jan.
Article en En | MEDLINE | ID: mdl-23959774
ABSTRACT
Malignant mesothelioma (MM) is an aggressive cancer of the mesothelium caused by asbestos. Asbestos use has been reduced but not completely stopped. In addition, natural or man-made disasters will continue to dislodge asbestos from old buildings into the atmosphere and as long as respirable asbestos is available, MM will continue to be a threat. Due to the long latency period of MM development, it would still take decades to eradicate this disease if asbestos was completely removed from our lives today. Therefore, there is a need for researchers and clinicians to work together to understand this deadly disease and find a solution for early diagnosis and treatment. This article focuses on developmental mechanisms as well as current therapies available for MM.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Amianto / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: J Cell Biochem Año: 2014 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Amianto / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: J Cell Biochem Año: 2014 Tipo del documento: Article